Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome

Worster, Andrew; Devereaux, P. J.; Heels‐Ansdell, Diane; Guyatt, Gordon; Opie, John C.; Mookadam, Farouk; Hill, Stephen A.

doi:10.1503/cmaj.045194

Cited by 68 publications

(50 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ST-segment elevation myocardial infarction adverse outcomes in patients namely increasing hospitalization days, requiring nursing home and skilled nursing facility for safe discharges, more morbidity and mortality and even poorer prognosis even after six months as they had high readmission rates. These findings complement [7][8][9] and expand the findings in the earlier study by Consumer-Sanchez et al 10 for predicting short-term prognosis and 1-year mortality for the first time and the study by Sinha et al 6 that people with high ischemia modified albumin (IMA) should be followed up carefully during hospitalization and post-discharge. There have been very little studies assessing the prognostic value of ischemia-modified albumin (IMA).…”

Section: Methodssupporting

confidence: 83%

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Nepal¹,

Jaisawal²,

Guragain³

et al. 2017

JCDR

View full text Add to dashboard Cite

Aims and Objectives: To find out if ischemia modified albumin can be a novel marker in ischemic heart disease. Materials and methods: Retrospective chart-review of chest pain patients who were evaluated in the emergency departments in 2006 and 2007. Results: Total of 400 patients presented with chest pain and subsequently were evaluated in the Emergency department at two major emergency departments associated with the teaching hospital associated Mercy Catholic Medical Center; few patients were excluded due to unavailability of complete data and follow-up visit in next six months. Thus, finally 351 patients met criteria for final analysis. Primary endpoints included the cardiac events and secondary outcomes were course in the hospital, days of hospitalization, interventions done in the hospital, disposition from the hospital, and readmission within next six months. Sensitivity and specificity of ischemia modified albumin (IMA) test was 80% and 50% respectively and positive predictive value and negative predictive values were 17% and 88% respectively. There were no further differences in cardiac events or interventions in higher ischemia modified albumin (IMA) group as compared to troponin (cTnT) (p=0.5). People with higher ischemia modified albumin (IMA) showed longer hospitalization days (p=0.025), needing nursing home or skilled nursing facility on discharge due to high discharge needs (p=0.0001) and had more readmissions as compared to troponin (p=0.02). However, Higher ischemia modified albumin (IMA) did not predict more cardiovascular events during hospital stay, rather troponin (cTnT) test predicted arrhythmia more than ischemia modified albumin (IMA) test (p=0.0001). Conclusion: Ischemia-modified albumin may be utilized as a novel marker of ischemia to rule out acute coronary syndrome along with troponin and electrocardiogram in the emergency departments. This test may also have short and long-term prognostic significances and may even be used as a surrogate marker in stroke, sepsis and thrombo-embolic diseases once these people need admission to the hospital.

show abstract

Section: Methodssupporting

confidence: 83%

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Nepal¹,

Jaisawal²,

Guragain³

et al. 2017

JCDR

View full text Add to dashboard Cite

show abstract

“…Worster A. et al found likelihood ratios 1.35 and 0.98 for IMA < and > 80 U/mL respectively within 6 hours after chest pain in order to predict [13] a serious cardiac outcome within the following 72 hours, suggesting IMA as a poor short term predictor of serious cardiac outcomes. Rafael Sadaba J. et al reduced [14] the mean tissue perfusion of the upper limb by 15.38% (p = 0.0005) using Technetium-99m human serum albumin after removal of the radial artery, but did not affect short term hand function. Steinbauer M. et al enhanced [15] the half-life and antioxidant activity of nitroxides by their covalent binding to human serum albumin, resulting in polynitroxyl albumin (PNA) in an IR hamster dorsal skinfold chamber model.…”

Section: Discussionmentioning

confidence: 98%

The Effect of the Antioxidant Drug U-74389G on Albumin Levels during Ischemia Reperfusion Injury in Rats

Tsompos¹,

Panoulis

Toutouzas³

et al. 2016

Acta Medica Bulgarica

View full text Add to dashboard Cite

Summary. This experimental study examined the effect of the antioxidant drug U-74389G on a rat model and particularly in a liver ischemia -reperfusion protocol. The effects of that molecule were studied biochemically using blood mean albumin levels. 40 rats of mean weight 231.875 g were used in the study. Albumin levels were measured at 60th min of reperfusion (groups A and C) and at 120th min of reperfusion (groups B and D). The drug U-74389G was administered only in groups C and D. U-74389G administration signifi cantly decreased the predicted albumin levels by 3.63% ± 0.87% (p = 0.0001). Reperfusion time non-signifi cantly increased the predicted albumin levels by 0.72% ± 1.04% (p = 0.4103). However, U-74389G administration and reperfusion time together signifi cantly decreased the predicted albumin levels by 2.02% ± 0.54% (p = 0.0005). U-74389G administration whether it interacted or not with reperfusion time has signifi cant decreasing short -term effects on albumin levels. It seems that the antioxidant capacity is associated with albumin catabolism.

show abstract

“…During a 1-month period in 2003, we enrolled patients in the study if they were Ն18 years of age, had possible cardiac ischemic symptoms within 6 h before presentation, and had a cardiac troponin test ordered by an ED physician (10 ). Patients were excluded from the study if they refused to participate, were referred directly to trauma or surgery, or had an outcome before the results of their first cardiac troponin test were known.…”

mentioning

confidence: 99%

Biomarkers for Predicting Serious Cardiac Outcomes at 72 Hours in Patients Presenting Early after Chest Pain Onset with Symptoms of Acute Coronary Syndromes

Kavsak¹,

Hill²,

Supapol

et al. 2012

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome

Cited by 68 publications

References 16 publications

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

The Effect of the Antioxidant Drug U-74389G on Albumin Levels during Ischemia Reperfusion Injury in Rats

Biomarkers for Predicting Serious Cardiac Outcomes at 72 Hours in Patients Presenting Early after Chest Pain Onset with Symptoms of Acute Coronary Syndromes

Contact Info

Product

Resources

About